Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-05-26
|
caplacizumab |
thrombotic thrombocytopenic purpura |
2 |
Ablynx (Belgium) |
Autoimmune diseases - Rare diseases |
2016-05-25
|
grass allergy immunotherapy |
grass allergy |
3 |
Circassia Pharmaceuticals (USA) |
Allergic diseases |
2016-05-25
|
ALKS 4230 (RDB 1450) and Keytruda® (pembrolizumab) |
advanced solid tumors |
1 |
Alkermes (Ireland) |
Cancer - Oncology |
2016-05-25
|
solithromycin |
mild to moderate community-acquired pneumonia (CABP) |
2 |
Cempra (USA - NC) Toyama Chemical (Japan) |
Infectious diseases |
2016-05-25
|
BAX 930/SHP655 |
hereditary thrombotic thrombocytopenic purpura |
1 |
Baxalta (USA - IL), now Shire (UK - USA) |
Autoimmune diseases - Rare diseases |
2016-05-25
|
Ovasave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy) |
Crohn disease |
2b |
TxCell (France) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-05-24
|
BI 655066/ABBV-066 (risankizumab) |
Crohn disease |
2 |
Abbvie (USA - IL) Boehringer Ingelheim (Germany) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-05-23
|
talazoparib |
advanced breast cancer |
2 |
QuantumLeap Healthcare Collaborative (USA - CA) Medivation (USA - CA) |
Cancer - Oncology |
2016-05-20
|
JNJ-61178104 |
|
1 |
Janssen Research & Development, a J&J company (USA - NJ) |
|
2016-05-20
|
lurbinectedin (PM1183) in combination with irinotecan |
advanced solid tumors |
1 |
PharmaMar (Spain) |
Cancer - Oncology |
2016-05-20
|
afatinib |
advanced/metastatic urothelial tract carcinoma |
2 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2016-05-19
|
MM-151 in combination with Onivyde® (irinotecan liposome injection) plus fluorouracil and leucovorin |
RAS wild-type metastatic colorectal cancer (mCRC) |
1 |
Merrimack Pharmaceuticals (USA - MA) Baxalta (USA - IL) |
Cancer - Oncology |
2016-05-19
|
talimogene laherparepvec |
breast cancer |
1-2 |
Amgen (USA - CA) |
Cancer - Oncology |
2016-05-19
|
combination regimens including MM-151, istiratumab (MM-141), seribantumab (MM-121) selected using a combination of genetic and nongenetic biomarkers |
colorectal cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck |
1 |
Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-05-19
|
Aplidin® (plitidepsin) in combination with bortezomib and dexamethasone |
relapsed and/or refractory multiple myeloma |
1 |
PharmaMar (Spain) |
Cancer - Oncology |
2016-05-18
|
XmAb®7195 |
|
1a |
Xencor (USA - CA) |
Allergic diseases - Inflammatory diseases - Respiratory diseases |
2016-05-18
|
Lymfactin® |
breast cancer associated secondary lymphedema |
1 |
Herantis Pharma (Finland) |
Cancer - Oncology |
2016-05-18
|
SYD985 (HER2-targeting antibody-drug conjugate based on trastuzumab and Synthon’s proprietary cleavable linker-duocarmycin (vc-seco-DUBA) payload) |
locally advanced or metastatic solid tumors including breast cancer, gastric cancer |
1 |
Synthon (The Netherlands) |
Cancer - Oncology |
2016-05-18
|
PBI-4050 |
cystic fibrosis-related diabetes |
2 |
ProMetic Life Sciences (Canada) |
Fibrotic diseases - Metabolic diseases |
2016-05-18
|
ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) |
infantile spasms |
preclinical |
Anavex Life Sciences (USA - NY) |
CNS diseases |